Sasitorn Siritho1, Douglas K Sato2, Kimihiko Kaneko3, Kazuo Fujihara3, Naraporn Prayoonwiwat4. 1. Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Thailand/Bumrungrad International Hospital, Thailand. 2. Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan/Department of Neurology, Faculty of Medicine, University of Sao Paulo, Brazil. 3. Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan. 4. Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Thailand naraporn.pra@mahidol.ac.th.
Abstract
BACKGROUND: Myelin oligodendrocyte glycoprotein (anti-MOG) antibody was reported in anti-aquaporin-4 (anti-AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD) patients. OBJECTIVES: To describe clinical phenotypes associated with anti-MOG. METHODS: Seventy consecutive Thai patients with inflammatory idiopathic demyelinating central nervous system disorders (IIDCD) who were previously anti-AQP4 seronegative were tested for anti-MOG. RESULTS: Anti-MOG was positive in six patients, representing 20.7% of the IIDCD anti-AQP4 seronegative patients with a non-multiple sclerosis phenotype, and most had relapses. All first presented with optic neuritis with good visual recovery after treatment. CONCLUSIONS: Anti-MOG positive patients may have manifestations that mimic NMOSD but differ in their course and prognosis from anti-AQP4 positive NMOSD.
BACKGROUND:Myelin oligodendrocyte glycoprotein (anti-MOG) antibody was reported in anti-aquaporin-4 (anti-AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD) patients. OBJECTIVES: To describe clinical phenotypes associated with anti-MOG. METHODS: Seventy consecutive Thai patients with inflammatory idiopathic demyelinating central nervous system disorders (IIDCD) who were previously anti-AQP4 seronegative were tested for anti-MOG. RESULTS: Anti-MOG was positive in six patients, representing 20.7% of the IIDCD anti-AQP4 seronegative patients with a non-multiple sclerosis phenotype, and most had relapses. All first presented with optic neuritis with good visual recovery after treatment. CONCLUSIONS: Anti-MOG positive patients may have manifestations that mimic NMOSD but differ in their course and prognosis from anti-AQP4 positive NMOSD.
Authors: Stefan M Gold; Anne Willing; Frank Leypoldt; Friedemann Paul; Manuel A Friese Journal: Semin Immunopathol Date: 2018-10-25 Impact factor: 9.623
Authors: Sara Mariotto; Salvatore Monaco; Patrick Peschl; Ilaria Coledan; Romualdo Mazzi; Romana Höftberger; Markus Reindl; Sergio Ferrari Journal: BMC Neurol Date: 2017-10-05 Impact factor: 2.474